GlassScriptPhysician profile
Olivia Czerniak
NPI 1376294462
$3,125.30
in general payments reported to CMS, 2019-2025
19 companies · $1,125 in 2025
The $1,125 reported for 2025 was more than what 87% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $38.97 · 2023: $694 · 2024: $1,268 · 2025: $1,125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,858 · Education: $228.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,858.40 |
| Education | $227.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $953.55 | 2024-2025 | Tecvayli, Rybrevant, Darzalex |
| E.R. Squibb & Sons, L.L.C. | $368.81 | 2024-2025 | Opdivo |
| Sobi, INC | $334.18 | 2022-2024 | |
| Genzyme Corporation | $235.10 | 2024-2025 | |
| Incyte Corporation | $174.99 | 2024 | Jakafi |
| Rigel Pharmaceuticals, INC. | $121.96 | 2023 | Tavalisse, Rezlidhia |
| Genentech USA, INC. | $121.60 | 2023 | Lunsumio |
| Agios Pharmaceuticals, INC. | $121.34 | 2023 | Pyrukynd |
| Alexion Pharmaceuticals, INC. | $121.15 | 2024 | |
| Karyopharm Therapeutics INC. | $113.18 | 2023 | Xpovio |
| Pfizer INC. | $96.00 | 2024 | |
| Pharmacosmos Therapeutics INC. | $88.03 | 2024-2025 | Monoferric |
| Genentech, INC. | $87.89 | 2024 | Tecentriq Hybreza, Polivy, Tecentriq |
| Stemline Therapeutics INC. | $69.44 | 2025 | Elzonris |
| Merck Sharp & Dohme LLC | $44.66 | 2024-2025 | Keytruda |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tempus Ai, INC | $27.15 | 2025 | Xt Cdx |
| Adaptive Biotechnologies Corporation | $18.19 | 2024 | Clonoseq |
| Regeneron Healthcare Solutions, INC. | $16.27 | 2024 | Libtayo |
| Takeda Pharmaceuticals U.S.A., INC. | $11.81 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olivia Czerniak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.